Scpharmaceuticals Ownership
| SCPH Stock | USD 3.68 0.23 6.67% |
Shares in Circulation | First Issued 2017-03-31 | Previous Quarter 39 M | Current Value 47 M | Avarage Shares Outstanding 24.4 M | Quarterly Volatility 11.5 M |
Scpharmaceuticals |
Scpharmaceuticals Stock Ownership Analysis
About 87.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.95. Scpharmaceuticals had not issued any dividends in recent years. scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts. SC Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people. To find out more about Scpharmaceuticals contact John Tucker at 617 517 0730 or learn more at https://www.scpharmaceuticals.com.Scpharmaceuticals Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Scpharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Scpharmaceuticals backward and forwards among themselves. Scpharmaceuticals' institutional investor refers to the entity that pools money to purchase Scpharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Kingdon Capital Management Llc | 2024-09-30 | 800 K | Stonepine Capital Management Llc | 2024-09-30 | 778.9 K | Awm Investment Company Inc | 2024-09-30 | 764.9 K | Nantahala Capital Management, Llc | 2024-09-30 | 750 K | State Street Corp | 2024-09-30 | 682.1 K | Geode Capital Management, Llc | 2024-09-30 | 643.3 K | Tejara Capital Ltd | 2024-12-31 | 612.9 K | Citadel Advisors Llc | 2024-09-30 | 526 K | Velan Capital Investment Management Lp | 2024-09-30 | 517.7 K | Orbimed Advisors, Llc | 2024-09-30 | 6.1 M | Rubric Capital Management Lp | 2024-09-30 | 4.8 M |
Scpharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Scpharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Scpharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Scpharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Scpharmaceuticals Outstanding Bonds
Scpharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Scpharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Scpharmaceuticals bonds can be classified according to their maturity, which is the date when Scpharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Scpharmaceuticals Corporate Filings
F4 | 12th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 31st of January 2025 Other Reports | ViewVerify | |
8K | 10th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 31st of December 2024 Other Reports | ViewVerify |
Currently Active Assets on Macroaxis
When determining whether Scpharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Scpharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Scpharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Scpharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Scpharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scpharmaceuticals. If investors know Scpharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scpharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.95) | Revenue Per Share | Quarterly Revenue Growth 1.641 | Return On Assets | Return On Equity |
The market value of Scpharmaceuticals is measured differently than its book value, which is the value of Scpharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Scpharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Scpharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scpharmaceuticals' market value can be influenced by many factors that don't directly affect Scpharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Scpharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Scpharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scpharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.